Last updated on September 2016

Safety Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas


Brief description of study

The Primary Objective is to evaluate the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma. The Secondary Objective is to evaluate the pharmacokinetics of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.

Clinical Study Identifier: NCT02891590

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jun Zhu, MD

Peking University Cancer Hospital
Beijing, China
  Connect »